top of page
HOME
ABOUT US
SOCIAL IMPACT
TEAM
PORTFOLIO
NEWSROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWSROOM
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa
Apr 1
ARCHIVE
September 2026
(1)
1 post
June 2026
(1)
1 post
May 2026
(1)
1 post
April 2026
(2)
2 posts
March 2026
(1)
1 post
October 2025
(1)
1 post
July 2025
(2)
2 posts
March 2025
(1)
1 post
January 2025
(1)
1 post
November 2024
(3)
3 posts
October 2024
(3)
3 posts
May 2024
(1)
1 post
April 2024
(1)
1 post
March 2024
(1)
1 post
January 2024
(1)
1 post
November 2023
(2)
2 posts
August 2023
(1)
1 post
June 2023
(1)
1 post
May 2023
(2)
2 posts
December 2022
(2)
2 posts
SEARCH BY TAGS
portfolio
(27)
27 posts
4BIO Ventures II
(21)
21 posts
investment
(11)
11 posts
4BIO Ventures III
(10)
10 posts
appointment
(9)
9 posts
collaboration
(8)
8 posts
SparingVision
(6)
6 posts
Orchard Therapeutics
(6)
6 posts
Ray Therapeutics
(5)
5 posts
acquisition
(5)
5 posts
publication
(4)
4 posts
advisory board
(4)
4 posts
Araris
(4)
4 posts
approval
(4)
4 posts
Ascend
(3)
3 posts
Trogenix
(3)
3 posts
CodeBio
(3)
3 posts
Takeda
(3)
3 posts
Spark Therapeutics
(3)
3 posts
ViaNautis
(3)
3 posts
Carisma
(2)
2 posts
clinical trials
(2)
2 posts
Kyowa Kirin
(2)
2 posts
TiGenix
(2)
2 posts
AAV
(2)
2 posts
Redpin Therapeutics
(2)
2 posts
review
(2)
2 posts
IPO
(2)
2 posts
ADC Therapeutics
(2)
2 posts
4BATLE
(1)
1 post
Cloverleaf
(1)
1 post
Chugai
(1)
1 post
awards
(1)
1 post
March Bio
(1)
1 post
ETF
(1)
1 post
merger
(1)
1 post
Taiho
(1)
1 post
EGLS
(1)
1 post
pricing
(1)
1 post
RMAT
(1)
1 post
Harbor Capital
(1)
1 post
Luca Science
(1)
1 post
AMED
(1)
1 post
Eli Lilly
(1)
1 post
DBJ
(1)
1 post
AI
(1)
1 post
Entact
(1)
1 post
Fierce 15
(1)
1 post
EBV
(1)
1 post
BLA
(1)
1 post
Moderna
(1)
1 post
results
(1)
1 post
venture
(1)
1 post
grant
(1)
1 post
Cytospire
(1)
1 post
Actithera
(1)
1 post
Insig AI
(1)
1 post
IND
(1)
1 post
Intellia
(1)
1 post
exit
(1)
1 post
Hornet Therapeutics
(1)
1 post
FOLLOW US
bottom of page